Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Recce Pharmaceuticals Ltd. ( (AU:RCE) ) is now available.
Recce Pharmaceuticals has released a webinar presentation primarily comprising standard disclaimers on the nature of its materials and legal limitations on reliance by prospective investors. The document emphasizes that the presentation is not financial advice, does not constitute an offer or solicitation to buy or sell securities, and that investors must conduct their own due diligence.
The company further stresses that any references to future plans, strategies or prospects are subject to significant risks and uncertainties, with no assurances that projected outcomes will be achieved. It also underscores restrictions on offering its securities in the United States, noting that its shares are not registered under U.S. securities laws and cannot be sold there without appropriate exemptions.
The most recent analyst rating on (AU:RCE) stock is a Sell with a A$0.42 price target. To see the full list of analyst forecasts on Recce Pharmaceuticals Ltd. stock, see the AU:RCE Stock Forecast page.
More about Recce Pharmaceuticals Ltd.
Recce Pharmaceuticals Ltd. is an Australian-listed biotechnology company focused on developing anti-infective therapies. The company operates in the pharmaceutical and life sciences sector, targeting unmet medical needs related to infectious diseases and drug-resistant pathogens.
Average Trading Volume: 100,213
Technical Sentiment Signal: Sell
Current Market Cap: A$135.9M
For a thorough assessment of RCE stock, go to TipRanks’ Stock Analysis page.